- Home
- MERC vs BDTX Comparison
MERC vs BDTX Comparison
Compare MERC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | BDTX |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 126.5M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MERC | BDTX |
|---|---|---|
| Price | $1.79 | $2.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.50 | ★ $10.40 |
| AVG Volume (30 Days) | ★ 775.4K | 623.1K |
| Earning Date | 05-13-2026 | 03-09-2026 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | N/A | ★ 32.45 |
| EPS | N/A | ★ 0.65 |
| Revenue | ★ $1,169,145,000.00 | N/A |
| Revenue This Year | $13.59 | N/A |
| Revenue Next Year | $10.79 | N/A |
| P/E Ratio | ★ N/A | $3.85 |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $1.48 | $1.20 |
| 52 Week High | $7.98 | $4.94 |
Technical Indicators
Market Signals| Indicator | MERC | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 51.11 |
| Support Level | $1.54 | $2.42 |
| Resistance Level | $2.25 | $2.86 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 36.09 | 65.69 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.